There remain unexplored potential treatments in HCL including anti-CD38 therapy such as daratumumab or isatuximab, or PD-1 inhibition given the recent discovery of high levels of PD-1 expression in HCL [6, 53]. This evidence concerns the gene CD38 and hairy cell leukemia.